These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11745443)

  • 21. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
    J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
    Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.
    Nicotra MR; Nisticò P; Mangoni A; Di Filippo F; Marincola FM; Natali PG
    J Immunother; 1997 Nov; 20(6):466-9. PubMed ID: 9409452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
    Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
    Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
    Wong RM; Scotland RR; Lau RL; Wang C; Korman AJ; Kast WM; Weber JS
    Int Immunol; 2007 Oct; 19(10):1223-34. PubMed ID: 17898045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.
    Le Poole IC; Riker AI; Quevedo ME; Stennett LS; Wang E; Marincola FM; Kast WM; Robinson JK; Nickoloff BJ
    Am J Pathol; 2002 Feb; 160(2):521-8. PubMed ID: 11839572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.
    Feder-Mengus C; Ghosh S; Weber WP; Wyler S; Zajac P; Terracciano L; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
    Br J Cancer; 2007 Apr; 96(7):1072-82. PubMed ID: 17342088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.
    Maeurer MJ; Gollin SM; Martin D; Swaney W; Bryant J; Castelli C; Robbins P; Parmiani G; Storkus WJ; Lotze MT
    J Clin Invest; 1996 Oct; 98(7):1633-41. PubMed ID: 8833913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
    Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
    Pittet MJ; Valmori D; Dunbar PR; Speiser DE; Liénard D; Lejeune F; Fleischhauer K; Cerundolo V; Cerottini JC; Romero P
    J Exp Med; 1999 Sep; 190(5):705-15. PubMed ID: 10477554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.
    Khammari A; Labarrière N; Vignard V; Nguyen JM; Pandolfino MC; Knol AC; Quéreux G; Saiagh S; Brocard A; Jotereau F; Dreno B
    J Invest Dermatol; 2009 Dec; 129(12):2835-42. PubMed ID: 19554023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
    Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P
    J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.